More on AVIR
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.15 |
|
|||
| Open | $5.21 | ||||
| 52 Wk High | $2.00 | ||||
| 52 Wk Low | $1.15 | ||||
| Day High | $5.31 | ||||
| Day Low | $5.20 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 71,613 | ||||
- Atea Pharmaceuticals (AVIR) PT Raised to $7 at Morgan Stanley
- Form 10-Q Atea Pharmaceuticals, For: Jun 30
- Form 8-K Atea Pharmaceuticals, For: Aug 12
- Aviragen Therapeutics (AVIR) Tops Q2 EPS by 15c
- Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
- Atea Pharmaceuticals HCV drug meets phase 3 trial endpoints
- Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
- Atea Pharmaceuticals starts Phase 1 trial of AT-587 for hepatitis E
- Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Entities mentioned with AVIR
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Stifel | View Related Stories »
- Show More...
